• KOL
    • Antiretroviral Therapy
    • Antonella D‘arminio D’arminio Monforte
    • Antonella D‘Arminio d’Arminio Monforte: Influence Statistics

      Antonella D‘Arminio d’Arminio Monforte

      Antonella D‘Arminio d’Arminio Monforte

      Show email address

      Infectious Diseases, University of Milan, Milan, Italy | ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy | University of Milan, Milan, Italy | Department ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Antonella D‘Arminio d’Arminio Monforte:Expert Impact

      Concepts for whichAntonella D‘Arminio d’Arminio Monfortehas direct influence:Antiretroviral therapy,Hiv infection,Infected patients,Highly active,Viral load,Cardiovascular disease,Myocardial infarction,Hiv infections.

      Antonella D‘Arminio d’Arminio Monforte:KOL impact

      Concepts related to the work of other authors for whichfor which Antonella D‘Arminio d’Arminio Monforte has influence:Antiretroviral therapy,Hiv infection,Human immunodeficiency virus,Infected patients,Viral load,Highly active,Cardiovascular disease.

      KOL Resume for Antonella D‘Arminio d’Arminio Monforte

      Year
      2022

      Infectious Diseases, University of Milan, Milan, Italy

      2021

      Clinic of Infectious Diseases, Polo Universitario Ospedale San Paolo, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

      2020

      ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy

      2019

      Department of Health Sciences, Institute of Infectious and Tropical Medicine, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

      2018

      Department of Health Sciences, Clinic of Infectious Diseases and Tropical Medicine, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy

      2017

      Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera–Polo Universitario San Paolo, Milan, Italy

      Department of Health Sciences, Clinic of Infectious Diseases and Tropical Medicine, S.Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan

      2016

      Clinic of Infectious Diseases, “San Paolo” Hospital, Milan, Italy

      2015

      Department of Infectious Diseases, Hospital San Paolo, University of Milan, Italy

      2014

      Department of Health Sciences, Clinic of Infectious Diseases, ‘San Paolo’ Hospital, University of Milan, Milan

      San Paolo Hospital

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Antonella D‘Arminio d’Arminio Monforte is among the top experts in the world.
      Concept World rank
      atv monotherapy nrtis #1
      virologically suppressive haart #1
      hcv rna 3c #1
      abc 1 january #1
      simplification patients #1
      mm3 month #1
      μl 2 death #1
      lpv nrtis #1
      efv abc #1
      201 patients covariation #1
      protease inhibitor retrospective #1
      antiretroviral therapies art #1
      clinical conditions tolerability #1
      r83k nrti treatment #1
      zidovudinecontaining regimens 95 #1
      age mcmd #1
      subset male patients #1
      geographical region incidence #1
      k43t v82a #1
      non‐aids events #1
      association endpoint #1
      infected late #1
      cfs inrs #1
      unfamiliar clinics #1
      one‐year cognitive follow‐up #1
      frax equation #1
      nonadherent persons #1
      hbv dna 2b #1
      intolerant haart regimen #1
      hiv1 tropism art #1
      severe covid19 subset #1
      year 1 drug #1
      ann virological response #1
      haart nonadherence #1
      post haart nir #1
      k55r v82a #1
      count increase #1
      hcv 3c #1
      antiretroviral regimens depression #1
      cirrhosis evr #1
      regimen 042 ritonavir #1
      failure confirmed #1
      study primary prophylaxis #1
      suppression point #1
      lopinavir treatment mutations #1
      lps haart #1
      1997patients #1
      hcv incidence time #1
      lamivudine low rates #1
      34 years 95 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Antonella D‘Arminio d’Arminio Monforte

      KOL-Index: 22969

      OBJECTIVE: To investigate the lymphoproliferative response (LPR) to human cytomegalovirus (HCMV) in two groups of AIDS patients undergoing long-term highly active antiretroviral therapy (HAART): group 1 ( n = 22) with nadir CD4(+) cell count <50/microl and no HCMV disease; group 2 ( n = 16) with <50/microl CD4(+) T-cell count and HCMV disease. All patients had previously undergone antiretroviral monotherapy or dual therapy before initiating HAART.

      STUDY DESIGN AND METHODS: The two groups ...

      Known for Hcmv Disease | Aids Patients | Lymphoproliferative Response | Lpr Haart | Cd4 Cell
      KOL-Index: 17569

      BACKGROUND: Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013.

      METHODS: We analysed data from 18 European and North American HIV-1 cohorts. ...

      Known for Patients Art | Life Expectancy | Antiretroviral Therapy | Collaborative Analysis | 3 Years
      KOL-Index: 16331

      Background: We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed patients with high CD4 count.

      Methods: We used data from 13 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, who were followed from the date they had CD4 count ≥350 cells/μL and were virologically suppressed (baseline). We used ...

      Known for Cd8 Ratio | Antiretroviral Therapy | Infected Patients | Immunodeficiency Virus | Cd4 Count
      KOL-Index: 15919

      BACKGROUND: Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovirals and the development of chronic kidney disease in people with initially normal renal function, as measured by estimated glomerular filtration rate (eGFR).

      METHODS: In ...

      Known for Chronic Kidney Disease | Filtration Rate | Estimated Glomerular | Normal Baseline | Positive Individuals
      KOL-Index: 15274

      OBJECTIVE: To evaluate the frequency of discontinuation of the first highly active antiretroviral regimen (HAART) and the factors predictive of discontinuing for toxicity and failure in a population-based cohort of HIV-positive individuals in Italy, naïve from antiretrovirals at enrolment.

      METHODS: The study population consisted of individuals who initiated HAART and had at least one follow-up visit. The primary end-points were discontinuation of any component of HAART for drug toxicity ...

      Known for Discontinuation Toxicity | Haart Regimen | Antiretroviral Naïve | 1 Year | Treatment Failure
      KOL-Index: 15260

      OBJECTIVE: To assess the diagnostic reliability of polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) for virus-associated opportunistic diseases of the central nervous system (CNS) in HIV-infected patients.

      DESIGN: CSF samples from 500 patients with HIV infection and CNS symptoms were examined by PCR. In 219 patients the PCR results were compared with CNS histological findings.

      METHODS: Nested PCR for detection of herpes simplex virus (HSV) type 1 or 2, varicella zoster virus ...

      Known for Central Nervous | Polymerase Chain Reaction | Infected Patients | Cmv Ebv | Cerebrospinal Fluid
      KOL-Index: 15187

      BACKGROUND: Patients with human immunodeficiency virus (HIV) infection and a history of Pneumocystis carinii pneumonia are at high risk for relapse if they are not given secondary prophylaxis. Whether secondary prophylaxis against P. carinii pneumonia can be safely discontinued in patients who have a response to highly active antiretroviral therapy is not known.

      METHODS: We analyzed episodes of recurrent P. carinii pneumonia in 325 HIV-infected patients (275 men and 50 women) in eight ...

      Known for Secondary Prophylaxis | Hiv Infection | Cubic Millimeter | Pneumocystis Carinii | Antiretroviral Therapy Patients
      KOL-Index: 14970

      BACKGROUND: The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype.

      METHODS: ...

      Known for Hcv Genotype | Antiretroviral Therapy | Highly Active | Haart Patients | Hepatitis Virus
      KOL-Index: 14241

      BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of randomised trials, we examined this question in prospective cohort studies.

      METHODS: We analysed data from 18 cohort studies of patients with HIV. Antiretroviral-naive patients from 15 of these studies were eligible for inclusion if they had started combination antiretroviral therapy (while AIDS-free, with a ...

      Known for Antiretroviral Therapy | Hiv Cohort | Aids Death | Deferred Initiation | 350 Cells Microl
      KOL-Index: 14216

      BACKGROUND: With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.

      METHODS: Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study ...

      Known for Death People | 1000 Personyears | Liver Disease | Multicohort Collaboration | Cd4 Cell Count
      KOL-Index: 14181

      BACKGROUND: Highly active antiretroviral therapy (HAART) has improved rates of CD4-lymphocyte recovery and decreased the incidence of HIV-1-related morbidity and mortality. We assessed whether prophylaxis against Pneumocystis carinii pneumonia (PCP) can be safely discontinued after HAART is started.

      METHODS: We investigated 7333 HIV-1-infected patients already enrolled in EuroSIDA, a continuing prospective observational cohort study in 52 centres across Europe and Israel. We did a ...

      Known for Pneumonia Prophylaxis | Haart Discontinuation | Incidence Pcp | Pneumocystis Carinii | Highly Active
      KOL-Index: 14018

      Ensuring timely access to care for persons with HIV is an important public health goal. To identify factors associated with delayed presentation to medical care after testing HIV-positive or with late HIV testing, we studied 968 patients at their first HIV care visit, enrolled in a multicenter study in Italy from 1997-2000. Patients completed a questionnaire on HIV-testing history, sexual behavior, and drug use behavior. Delayed presenters were patients with >6 months between their first ...

      Known for Delayed Presentation | Late Testing | Multicenter Study | Timely Access | Sexual Behavior
      KOL-Index: 13768

      OBJECTIVES: To analyse the virological and clinical efficacy of cidofovir combined with highly active antiretroviral therapy (HAART) in AIDS-related progressive multifocal leukoencephalopathy (PML).

      DESIGN: Multicentre observational study of consecutive HIV-positive patients with histologically or virologically-proven PML. Group A, 26 patients treated with HAART; group B, 14 patients treated with HAART plus cidofovir 5 mg/kg intravenously per week for the first 2 weeks and alternate ...

      Known for Cidofovir Haart | Progressive Multifocal | Jc Virus | 2 Weeks | Leukoencephalopathy Pml
      KOL-Index: 13412

      OBJECTIVES: The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretroviral therapy (HAART) in an Italian cohort.

      METHODS: We included in the study patients from the Italian COhort Naïve Antiretrovirals (ICoNA) who initiated HAART when naïve to antiretroviral therapy (ART). The endpoints were discontinuation within the first year of >or= 1 drug in the first HAART ...

      Known for Antiretroviral Therapy | Highly Active | Intolerance Toxicity | Discontinuation 1 Drug | Time Haart

      Key People For Antiretroviral Therapy

      Top KOLs in the world
      #1
      Andrew N Phillips†
      antiretroviral therapy viral load hiv infection
      #2
      Jens Dilling Lundgren
      antiretroviral therapy hiv infection viral load
      #3
      Peter Reiss†
      antiretroviral therapy hiv infection myocardial infarction
      #4
      David A Cooper
      antiretroviral therapy hiv infection viral load
      #5
      Joseph J Eron
      antiretroviral therapy united states hiv infection
      #6
      Douglas D Richman†
      antiretroviral therapy hiv infection human immunodeficiency virus

      Infectious Diseases, University of Milan, Milan, Italy | ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy | University of Milan, Milan, Italy | Department of Health Sciences (DISS), University of Milan, Milan, Italy | Ospedale Sa

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.